140 related articles for article (PubMed ID: 18798097)
1. What is the role of 18F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?
Gill S; Hicks RJ; Seymour JF
Leuk Lymphoma; 2008 Sep; 49(9):1653-6. PubMed ID: 18798097
[No Abstract] [Full Text] [Related]
2. [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma.
Gill S; Wolf M; Prince HM; Januszewicz H; Ritchie D; Hicks RJ; Seymour JF
Clin Lymphoma Myeloma; 2008 Jun; 8(3):159-65. PubMed ID: 18650179
[TBL] [Abstract][Full Text] [Related]
3. F-18 FDG PET/CT imaging in recurrent mantle cell lymphoma presenting with cauda equina syndrome.
Bilici A; Ustaalioglu BB; Seker M; Canpolat N; Gumus M
Clin Nucl Med; 2010 Mar; 35(3):211-2. PubMed ID: 20173464
[No Abstract] [Full Text] [Related]
4. Positron emission tomography in the management of patients with indolent non-Hodgkin's lymphoma.
Naumann R; Beuthien-Baumann B
Clin Lymphoma; 2003 Jun; 4(1):50-1. PubMed ID: 12837155
[No Abstract] [Full Text] [Related]
5. 18F-FDG PET/CT in a case of bilateral lacrimal gland infiltration by mantle cell lymphoma.
Martínez-Esteve A; García-Gómez FJ; Borrero-Martin JJ; Fajardo-Pico E; Borrego-Dorado I
Rev Esp Med Nucl Imagen Mol; 2015; 34(6):396-7. PubMed ID: 25956958
[No Abstract] [Full Text] [Related]
6. Positron emission tomography in mantle cell lymphoma.
Brepoels L; Stroobants S; De Wever W; Dierickx D; Vandenberghe P; Thomas J; Mortelmans L; Verhoef G; De Wolf-Peeters C
Leuk Lymphoma; 2008 Sep; 49(9):1693-701. PubMed ID: 18798104
[TBL] [Abstract][Full Text] [Related]
7. Fluorodeoxyglucose-positron-emission tomography findings in mantle cell lymphoma.
Alavi A; Shrikanthan S; Aydin A; Talanow R; Schuster S
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):261-6. PubMed ID: 21658653
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab.
Lamonica D; Graf DA; Munteanu MC; Czuczman MS
J Nucl Med; 2017 Jan; 58(1):62-68. PubMed ID: 27469362
[TBL] [Abstract][Full Text] [Related]
9. Bilateral Renal Involvement in Mantle Cell Lymphoma on FDG PET/CT.
Mukherjee A; Agarwal KK; Gogia A; Bal C; Kumar R
Clin Nucl Med; 2016 Apr; 41(4):e206-7. PubMed ID: 26914553
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of mantle-cell lymphoma relapse by 18F-FDG PET/CT after water gastric distention.
Banzo I; Martínez-Rodríguez I; Quirce R; Jiménez-Bonilla J; Carril JM
Clin Nucl Med; 2014 Oct; 39(10):931-3. PubMed ID: 24999694
[TBL] [Abstract][Full Text] [Related]
11. Neurological picture. FDG-PET in meningeal lymphomatosis.
Shinohara M; Kosaka S; Okamura T; Yamamoto T
J Neurol Neurosurg Psychiatry; 2007 Sep; 78(9):974. PubMed ID: 17702776
[No Abstract] [Full Text] [Related]
12. 18F-FDG PET/CT in Intramuscular Mantle Cell Lymphoma With Elongated Lymphomatous Neurovascular Extension.
Hod N; Levin D; Anconina R; Ezroh Kazap D; Lantsberg S
Clin Nucl Med; 2019 Apr; 44(4):e298-e300. PubMed ID: 30688737
[TBL] [Abstract][Full Text] [Related]
13. Perirenal Involvement of Mantle Cell Lymphoma: Imaging Features.
Ufuk F; Karaman E; Karabulut N
Urology; 2016 Nov; 97():e1-e3. PubMed ID: 27233934
[TBL] [Abstract][Full Text] [Related]
14. The mysteries of mantle cell lymphoma--do PET scans provide a clue?
Link BK
Leuk Lymphoma; 2008 Sep; 49(9):1662-3. PubMed ID: 18798100
[No Abstract] [Full Text] [Related]
15. Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project.
Bailly C; Carlier T; Berriolo-Riedinger A; Casasnovas O; Gyan E; Meignan M; Moreau A; Burroni B; Djaileb L; Gressin R; Devillers A; Lamy T; Thieblemont C; Hermine O; Kraeber-Bodéré F; Le Gouill S; Bodet-Milin C
Haematologica; 2020 Jan; 105(1):e33-e36. PubMed ID: 31371411
[No Abstract] [Full Text] [Related]
16. Giant Cell Tumor of the Tendon Sheath With Discordant Metabolism as a False Positive on Staging of Mantle Cell Lymphoma.
Rezaee A; Chen W; Dilsizian V; Chen Q; Kimball AS
Clin Nucl Med; 2015 Oct; 40(10):814-5. PubMed ID: 26053722
[TBL] [Abstract][Full Text] [Related]
17. FDG-PET/CT response assessment with qualitative Lugano criteria outperforms change in SUV
Russler-Germain DA; Calhoun BR; Wu N; Watkins MP; Siegel BA; Bartlett NL; Mhlanga JC
Leuk Lymphoma; 2023; 64(11):1870-1874. PubMed ID: 37489928
[No Abstract] [Full Text] [Related]
18. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma.
Ulaner GA; Lilienstein J; Gönen M; Maragulia J; Moskowitz CH; Zelenetz AD
J Clin Oncol; 2014 Jan; 32(1):51-6. PubMed ID: 24248697
[TBL] [Abstract][Full Text] [Related]
19. FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome.
Karam M; Ata A; Irish K; Feustel PJ; Mottaghy FM; Stroobants SG; Verhoef GE; Chundru S; Douglas-Nikitin V; Oliver Wong CY; Brepoels LM
Nucl Med Commun; 2009 Oct; 30(10):770-8. PubMed ID: 19657307
[TBL] [Abstract][Full Text] [Related]
20. [18F]fluorodeoxyglucose positron emission tomography in the management of lymphomas.
Kostakoglu L
Clin Lymphoma Myeloma; 2008 Oct; 8(5):273-6. PubMed ID: 18854280
[No Abstract] [Full Text] [Related]
[Next] [New Search]
